Pepscope Secures €4.3 million Investment to Develop and Commercialize QuantaKinome
Pepscope has secured a 4.3-million-euro funding round, led by KIKK Capital, together with Oost NL and the Netherlands Enterprise Agency to further develop and commercialize her lead product QuantaKinome™.
QuantaKinome™ is the first technology to provide direct insights into the activities of hundreds of protein kinases simultaneously inside the cells of diseased tissues. Pepscope offers QuantaKinome™ to the pharmaceutical industry and academic researchers to improve the discovery and development of novel kinase inhibitors and other therapeutic compounds, to find new applications of existing compounds, and in due course to select optimal therapies for individual patients.
Kinase inhibitors represent an essential class of targeted therapies that exert their effects by influencing signaling networks inside cells, governed by protein kinases. Despite impressive scientific progress, little is known about the complex effects of drugs on these networks inside tissues. QuantaKinome™ is perfectly positioned to fill this gap.
Anna Ressa, CEO & co-founder of Pepscope, comments: “With this investment, we are fully equipped to expand our business globally and work on novel solutions for drug development with pharmaceutical partners. I am very proud of the strong and dedicated Pepscope team that brings QuantaKinome™ to the market.”
“Pepscope solves a crucial problem with an enormous, untapped market potential”, says Johan Sebregts, Managing Partner of lead investor KIKK Capital, “We are proud to join Pepscope together with our partners and bring our combined financial and business resources to the table to help the company grow.”
"Pepscope has a promising solution for improving drug development, leading to personalized treatment plans and more effective care," says Thomas Hensel, Investment Manager at Oost NL. Oost NL provides a loan to Pepscope from the new fund ION+.
“We’re delighted that we can finally offer a solution for the lack of insight in kinase activities in cells and tissues”, adds Jos Joore, co-founder of Pepscope, “QuantaKinome™ is bound to transform kinase inhibitors and other therapies. We can’t wait to start making an impact on patient lives.”
For more information: www.pepscope.com
